

# 2020 Sustainability Accounting Standards Board (SASB) Mapping Report

---



# 2020 Sustainability Accounting Standards Board (SASB) Mapping Report

We understand that our investors and other stakeholders are interested in understanding Jazz’s performance in a broader way to include environmental, social and governance perspectives. This 2020 mapping report is Jazz Pharmaceuticals’ first year of mapping these disclosures to the SASB framework for the Biotechnology and Pharmaceuticals industry.

**We provide information on Jazz’s activities on our website and in our Annual Report and Proxy Statement, including in the following areas:**

 Access to Medicine, Patients and Community

 Governance

 Culture and Human Capital Management

 COVID-19 Response

 Environmental Sustainability

 Ethics

Please review Jazz’s [Annual Report and Proxy Statement](#) for further information about the company’s corporate responsibility and sustainability efforts.

SASB TOPIC	CODE	ACCOUNTING METRIC	INFORMATION
<b>Safety of Clinical Trial Participants</b>	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Jazz Pharmaceuticals is committed to protecting the rights and well-being of participants enrolled in clinical trials. We have implemented relevant quality and regulatory compliance systems that conform to our internal requirements and that are designed to comply with applicable laws. These systems are described in quality standards, policies, standard operating procedures and training programs. They incorporate a management review process that includes quality audits and system effectiveness reviews.

**Disclosure Statement:** Jazz Pharmaceuticals’ 2020 mapping report provides information regarding company goals, efforts and objectives and otherwise includes forward-looking statements. Some material is referenced to other company documents or portions of Jazz Pharmaceuticals’ website, and links are provided to those documents or portions of Jazz Pharmaceuticals’ website where appropriate. Jazz Pharmaceuticals’ goals, efforts and objectives are aspirational and are not guarantees or promises that such goals, efforts and objectives will be met. Jazz Pharmaceuticals’ actual results and the timing of events could differ materially from those anticipated in such aspirational and other forward-looking statements. See Appendix A hereto for additional important information about these aspirational and other forward-looking statements.

SASB TOPIC	CODE	ACCOUNTING METRIC	INFORMATION
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	We had <b>1 FDA PV inspection in June 2019</b> . This resulted in a FDA Form 483 with 3 observations. Voluntary action indicated. We have implemented corrective actions and improvements as communicated to the FDA.
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Not reported.
<b>Access to Medicines</b>	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Our access focus has been on Expanded/Early Access Programs (EAPs), where consistent with applicable laws and regulations, when there is sufficient evidence of the safety and effectiveness of the investigational medicine to support its use in the particular circumstance.  See our <a href="#">Expanded Access</a> .
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	No Jazz products are on the list at time of reporting.
<b>Affordability &amp; Pricing</b>	HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Not reported.
	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not reported.
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported.

SASB TOPIC	CODE	ACCOUNTING METRIC	INFORMATION
<b>Drug Safety</b>	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Available via the <a href="#">FDA Adverse Reporting Website</a> .
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Available via the <a href="#">FDA Adverse Reporting Website</a> .
	HC-BP-250a.3	Number of recalls issued, total units recalled	Jazz conducted one partial lot recall of Erwinase in one international market in 2018.
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	Not reported.
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Not reported.
<b>Counterfeit Drugs</b>	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	<p>In some markets, we distribute our medicines ourselves, but in other markets, including the U.S., we use third-party distributors. In all cases in which we use service providers, we enter into quality and technical agreements with the service providers in an effort to protect the integrity of the process.</p> <p>Further, in both Europe and the U.S. our medications are packaged and labeled with individual serial numbers, making them much easier to track and making counterfeits easier to identify. Serialized numbering allows identification to be checked throughout the supply chain. If a serial number scan is not valid, it provokes an alert and an investigation is undertaken to verify whether the medication in question is a legitimate Jazz product.</p> <p>For more information, please see our <a href="#">Annual Report</a>.</p>
	HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	If our alert and investigation systems determine that a particular product may be counterfeit or falsified, we have defined procedures in place designed to alert our customers, business partners and regulatory authorities. Our procedures require us to perform and document root cause investigation, corrective and preventive actions.

SASB TOPIC	CODE	ACCOUNTING METRIC	INFORMATION
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Not reported.
<b>Ethical Marketing</b>	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Not reported.
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	See our <a href="#">Code of Conduct</a> .
<b>Employee Recruitment, Development &amp; Retention</b>	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	For information about our recruitment and retention efforts, see the Culture and Human Capital Management section of our <a href="#">Proxy Statement</a> and the <a href="#">Culture</a> page on our website.
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Not reported.
<b>Supply Chain Management</b>	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	Jazz Pharmaceuticals does not participate in the RX 360 International Pharmaceutical Supply Chain Consortium's audit program but has engaged an independent third party to conduct an end-to-end supply chain and brand protection audit.
<b>Business Ethics</b>	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Not reported.
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	See our <a href="#">Code of Conduct</a> .
<b>Activity Metric</b>	HC-BP-000.A	Number of patients treated	Not reported.
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	1. See <a href="#">Our Medicines</a> . 2. See <a href="#">Our Pipeline</a> .

## APPENDIX A

---

**Special Note Regarding Forward-Looking Statements.** This Jazz Pharmaceuticals' 2020 mapping report contains or references forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' goals, efforts and objectives, including Jazz Pharmaceuticals' efforts to comply with laws, rules, regulations, standards and corporate policies that apply to its business as well as its efforts to protect the integrity of its supply chain; the design and goals of Jazz Pharmaceuticals' Employee Diversity and Inclusion program; Jazz Pharmaceuticals' continued investment in an evolving and growing research and development focus; and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, goals, efforts, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID-19 pandemic and resulting global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to Jazz Pharmaceuticals' business operations; the time-consuming and uncertain regulatory approval process, including the risk that Jazz Pharmaceuticals' planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those being experienced, and expected to continue to be experienced, by Jazz Pharmaceuticals as a result of the effects of the COVID-19 pandemic; delays or problems in the supply or manufacture of Jazz Pharmaceuticals' products and product candidates; complying with applicable U.S. and non-U.S. legal and regulatory requirements, including those governing pharmaceutical advertising laws or the regulations permitting sales under early access or named patient programs; government investigations, legal proceedings and other actions; obtaining and maintaining adequate coverage and reimbursement for Jazz Pharmaceuticals' products; challenges inherent in efficiently managing employees in diverse geographies and creating a positive workplace culture; and other risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements included or referenced in this 2020 mapping report are made only as of the date of this 2020 mapping report or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

---



Jazz Pharmaceuticals®